Skip to main content

Table 2 Previous prophylactic therapies of erenumab patients

From: Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany

Medical therapiesa

Previous therapy

N (%)

Contraindication against therapy

N (%)

 Topiramate

461 (85.1)

41 (7.6)

 Beta blocker

437 (80.6)

68 (12.5)

 Amitriptyline

390 (72.0)

81 (14.9)

 Flunarizine

270 (49.8)

167 (30.8)

 Onabotulinumtoxin Ab

204 (37.6)

8 (1.5)

 Valproate

107 (19.7)

249 (45.9)

 Others

406 (74.9)

-

 No previous therapy

9 (1.7)

 

 No contraindications

-

217 (40.0)

Number of previous therapies, mean (SD)

3.4 (1.4)

 

Number of previous therapies and contraindications, mean (SD)

4.6 (1.4)

Non-medical therapies

 

N (%)

 Yes

 

406 (74.9)

 No

 

136 (25.1)

 Relaxation therapies

 

338 (62.4)

 Physical exercise (sports)

 

270 (49.8)

 Acupuncture

 

219 (40.4)

 Psychological therapy of pain

 

168 (31.0)

  1. SD standard deviation, N 542 (number of patients)
  2. aMultiple responses were possible
  3. bOnly patients with chronic migraine additionally received onabotulinum A (i.e. 75.3 % of CM patients)